Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds and mediates endo-lysosomal degradation of low-density lipoprotein receptor (LDLR), limiting plasma clearance of cholesterol-rich LDL particles in liver. Gain-of-function (GOF) point mutations in PCSK9 are associa...
Main Authors: | Samantha K. Sarkar, Angela Matyas, Ikhuosho Asikhia, Zhenkun Hu, Mia Golder, Kaitlyn Beehler, Tanja Kosenko, Thomas A. Lagace |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2022.960272/full |
Similar Items
-
Loss of Hepatic Surf4 Depletes Lipid Droplets in the Adrenal Cortex but Does Not Impair Adrenal Hormone Production
by: Xiaole Chang, et al.
Published: (2021-11-01) -
Corrigendum: Loss of hepatic Surf4 depletes lipid droplets in the adrenal cortex but does not impair adrenal hormone production
by: Xiaole Chang, et al.
Published: (2023-05-01) -
Efficacy of Evolocumab in Patients with Hypercholesterolemia
by: Xuan Jin, et al.
Published: (2020-12-01) -
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01) -
PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)